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Abstract: Prior studies have demonstrated the importance of treatment persistence with anti-
psychotic agents in sustaining control of schizophrenic symptoms. However, the conventional 
approach in measuring treatment persistence tended to use only the ﬁ  rst prescription episode 
even though some patients received multiple prescriptions (or multiple treatment episodes) of 
the same medication within one year following the initiation of the index drug. In this study, 
we used data from the Veterans Health Administration in the United States to assess the extent 
to which patients received multiple prescriptions. The study found that about a quarter of the 
patients had two or more treatment episodes and that levels of treatment persistence tended to vary 
across treatment episodes. Based on these results, we offered an alternative approach in which 
we calculated treatment persistence with typical and atypical antipsychotic agents separately 
for patients with one, two, or three treatment episodes. Considering that patients with different 
number of treatment episodes might differ in disease proﬁ  les, this treatment episode-speciﬁ  c 
approach offered a fair comparison of the levels of treatment persistence across patients with 
different number of treatment episodes. Future research needs to extend the analyses beyond 
two antipsychotic classes to individual antipsychotic agents. A more comprehensive assessment 
using appropriate analytic methods should help physicians make prescription choices that will 
ultimately improve the care of patients with schizophrenia.
Keywords: treatment persistence (or discontinuation), treatment episode, antipsychotic agents, 
schizophrenia
Introduction
Prior studies have demonstrated the efﬁ  cacy and effectiveness of both typical (1st gen-
eration) and atypical (2nd generation) antipsychotic agents in reducing schizophrenic 
symptoms (Purdon et al 2000; Hirsch et al 2002; Kane et al 2002). However, the likeli-
hood of sustaining control of schizophrenic symptoms depends on the persistence of 
treatment (Vanelli et al 2001; Menzin et al 2003). The importance of sustained treat-
ment in the clinical management of schizophrenia, coupled with known differential 
side effects associated with typical and atypical antipsychotic agents (Kane 1996; 
Allison et al 1999; Leucht et al 1999; Leslie and Rosenheck 2001), has generated a 
lot of interest in comparing treatment persistence across antipsychotic agents (APA 
1997; Lehman and Steinwachs 1998; VA 1998; Valenstein et al 2002; Docherty et al 
2003; Lehman et al 2004; Lieberman et al 2005; Ren et al 2006).
In assessing treatment persistence across different antipsychotic agents, prior 
studies have indicated that although antipsychotic agents signiﬁ  cantly reduce the 
symptoms of schizophrenia, poor treatment persistence is quite common among many 
patients with schizophrenia (APA 1997; Lehman and Steinwachs 1998; VA 1998; Neuropsychiatric Disease and Treatment 2007:3(2) 278
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Rosenheck 1999). Other studies reported that there were no 
statistically signiﬁ  cant differences in the levels of treatment 
persistence of either typical or atypical antipsychotic agents 
(Citrome and Volavska 2002; Dolder et al 2002), with about 
44% and 48% of patients with schizophrenia continued to 
reﬁ  ll their prescriptions for atypical and typical antipsychotic 
agents, respectively (Vanelli et al 2001).
The existing body of literature focusing on the compari-
sons among antipsychotic agents with regard to treatment 
persistence remains largely problematic. In most of the 
studies, treatment persistence or time to “discontinuation” or 
“switching” to another antipsychotic agent is often calculated 
in terms of mean number of days from ﬁ  rst “initiation” to 
ﬁ  rst discontinuation or a ﬁ  rst gap of >15 or >30 days (Haynes 
2001). This measurement of treatment persistence does not 
take into account the number of days from second or third 
“initiation” to second or third discontinuation of treatment 
(or treatment episodes beyond the ﬁ  rst prescription). Because 
patients who switch back to the same antipsychotic agent 
for a second or third time within a year may represent more 
complicated cases, treatment persistence using only the ﬁ  rst 
treatment episode while excluding subsequent treatment 
episodes during a speciﬁ  ed study period may yield biased 
results. Thus, in this present study, we offered an alternative 
approach, which included patients with multiple prescriptions 
of the same antipsychotic agent within a year following the 
initiation of the index drug. We also compared levels of 
treatment persistence, using conventional and our alterna-
tive approach, between typical and atypical antipsychotic 
agents.
Methods
The study used two existing databases from the VA: (1) 
pharmacy data from the VA National Pharmacy Beneﬁ  ts 
Management Program (PBM) and (2) VA national admin-
istrative data. The VA is the largest integrated health care 
system in the United States, with approximately 4.2 million 
enrollees and about 5% of the total US market share for 
hospital services. The VA administrative data consist of 
outpatient ﬁ  les, which provide information system about all 
outpatient clinic visits in the VA, and inpatient ﬁ  les, which 
provide medical information about all discharges from VA 
inpatient settings, including ICD-9-CM codes represent-
ing admitting and discharge diagnoses (Lamoreaux 1996). 
We identiﬁ  ed patients with schizophrenia using the 295.xx 
ICD-9-CM codes from the outpatient and inpatient ﬁ  les. To 
increase speciﬁ  city of the ICD-9-CM codes for schizophrenia, 
the study further identiﬁ  ed patients with >1 inpatient or >2 
Valenstein et al 2002; Lehman et al 2004; Lieberman et al 
2005). One study indicated that about 60%–79% of patients 
with schizophrenia who participated in the study discontinued 
pharmacologic treatment within a few months (Tafesse et 
al 2003). Another study reported that about 50% of patients 
with schizophrenia did not take their prescribed medications 
as directed (Lacro et al 2002). Similarly, studies using data 
from the Veterans Health Administration (VA) revealed 
that about 50% of the patients with schizophrenia who were 
discharged from hospitals did not remain in treatment over 
time (VA 2002). These ﬁ  ndings were recently corroborated 
by the CATIE (Clinical Antipsychotic Trials of Intervention 
Effectiveness) trial, which reported that as many as 74% of 
the patients discontinued medication treatment before the 
18th month following the start of the CATIE trial (Lieber-
man et al 2005).
Poor treatment persistence of antipsychotic agents has 
been well documented to result in poor patient outcomes 
(Ayuso-Gutierrez and Vega 1997; Svarstaad et al 2001; Men-
zin et al 2003; Lehman et al 2004). Using California Medicaid 
(MediCal) prescription and medical claims data, Tafesse 
and colleagues examined the relationship between treatment 
persistence of antipsychotic medications and hospitalization 
among patients with schizophrenia (Tafesse et al 2003). The 
study yielded results indicating that patients with poor treat-
ment persistence were 1.5 times more likely to be readmitted 
compared to patients with better treatment persistence. This 
result was also reported in a study by Grogg and colleagues, 
in which they found that patients with low adherence were 
49% more likely to have an inpatient hospitalization when 
compared with compliant patients (Grogg et al 2002).
Recognizing the importance of treatment persistence in 
controlling symptoms of schizophrenia, a number of studies 
have compared levels of treatment persistence across differ-
ent antipsychotic agents (Cramer and Rosenheck 1999; Dixon 
et al 1999; Vanelli et al 2001; Dolder et al 2002; Zhu et al 
2003; Ren et al 2006). However, the results of these studies 
tend to be mixed. For instance, some studies indicated that 
the use of atypical antipsychotic agents was associated with 
signiﬁ  cantly less treatment switching than the use of typi-
cal antipsychotic agents (Menzin et al 2003), and that only 
about 11% of patients with schizophrenia who were receiving 
typical antipsychotic agents achieved uninterrupted therapy, 
with a mean duration of 142 days over a year, or 39% of 
days covered (McCombs et al 1999). Another study based 
on the VA database, however, reported that treatment persis-
tence with atypical antipsychotic agents was only modestly 
better than that with typical antipsychotic agents (Cramer and Neuropsychiatric Disease and Treatment 2007:3(2) 279
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outpatient ICD-9-CM codes (>7 days apart) of schizophrenia. 
This approach has been shown to increase speciﬁ  city without 
sacriﬁ  cing sensitivity (Leslie and Rosenheck 2001).
Pharmacy data came from the VA National Drug For-
mulary, which are automated uniformly throughout the VA 
system, and are updated monthly. The national pharmacy 
data consist of extensive prescription information for all VA 
patients who obtain their prescriptions in the VA system. This 
centralized database provides comprehensive prescription 
information: medication class, dose, dates of issues, ﬁ  lls, 
reﬁ  lls, and dispenses, quantity of pills dispensed, and number 
of days of medication dispensed. At the time of the study, 
the veterans enrolled in the VA are entitled to medications 
with a US $7.00 co-payment arrangement. The economic 
incentive for veterans is almost always to obtain medica-
tions through VA medical centers rather than from other 
systems of care. This system allows for tracking almost all 
antipsychotic medications, whereas in other civilian systems 
this might be extremely difﬁ  cult given multiple sources for 
obtaining initial and reﬁ  ll prescriptions such as pharmacy 
chains. Using the pharmacy data for VA ﬁ  scal years (FY) 
2000, 2001, 2002, 2003, and 2004, we deﬁ  ned “initiation” 
using a 6-month “clean” period in which a patient was not on 
the target drug prior to initiation. More speciﬁ  cally, patients 
were initiated on the target drug at any point of time within 
one year provided that they had not been on the target drug 
for 6 months prior to initiation. We reserved one year follow-
ing the initiation to calculate treatment persistence. Based on 
this deﬁ  nition of initiation, we created two non-overlapping 
periods using a ﬂ  oating date approach: 10/1/1999–3/31/2002 
and 10/1/2002–3/31/2005.
Treatment persistence was measured as the length of time 
where a patient was continuously on any antipsychotic agents 
included in the study until discontinuation of treatment or 
until the ﬁ  rst gap of >15 days without the target medication. 
We also conducted sensitivity analysis using a gap of >30 
days as treatment discontinuation. Unlike the conventional 
approach, which included only the ﬁ  rst treatment episode, 
in calculating treatment persistence, the alternative approach 
that we proposed in the study incorporated all treatment 
episodes by calculating treatment persistence separately 
among patients with one treatment episode, among patients 
with two treatment episodes, and among patients with three 
treatment episodes.
Since poor treatment persistence is associated with poor 
tolerability of the side-effects of the medications, we opted 
to compare typical versus atypical antipsychotic agents, 
which are known to differ in side-effect proﬁ  les (Allison 
et al 1999; Chakos et al 2002). For typical antipsychotic 
agents as a class, we selected three agents, representing high 
potency (haloperidol), medium potency (perphenazine), and 
low potency (chlorpromazine), whereas for atypical antipsy-
chotic agents as a class, we included three most commonly 
prescribed agents during period 1: olanzapine, risperidone, 
and quetiapine, and we added ziprasidone during period 2. 
It is important to note that treatment persistence was mea-
sured at the individual drug level and then aggregated to the 
drug class level. For instance, for typical agents, if patient 
A switched from one typical to another typical, and patient 
B switched from one typical to one atypical, then treatment 
persistence was measured by taking the average of patient 
A’s and B’s length of time from the initiation date of the 
target drug to the date when the switch took place for the 
two patients, respectively. 
Results
Based on the above-described procedures, we found that it 
was quite common for patients with schizophrenia to have 
multiple prescriptions of the same antipsychotic agent after 
discontinuation, deﬁ  ned either as a gap of >15 or >30 days, 
within one year following the initiation of the index drug. As 
shown in Table 1, between 10/1/1999 and 3/31/2002 when 
using a gap of >15 days to deﬁ  ne treatment discontinuation, 
as many as 25% of the patients had multiple prescriptions 
of the same drug for both typical and atypical antipsychotic 
agents. This ﬁ  nding was corroborated by sensitivity analyses 
using both a gap of >30 days in deﬁ  ning treatment discon-
tinuation as well as using data from period 2, or between 
10/1/2002 and 3/31/2005. Based on these results, we opted 
to use the ﬁ  rst three treatment episodes to calculate treatment 
persistence, which captured about 98% or 99% of the patients 
using >15 days or >30 days as treatment discontinuation, 
respectively.
Using conventional approach in calculating treatment 
persistence, we found that patients taking atypical agents 
were more compliant than patients taking typical agents as 
exempliﬁ  ed by the higher levels of treatment persistence 
(Table 2). During the period between 10/1/1999 and 3/31/2002, 
patients taking atypical agents remained on the index drug for 
150 days (until there was a gap of >15 days) following initia-
tion as compared to 107 days for those taking typical agents 
(p < 0.001). During the same period, patients taking atypical 
agents remained on the index drug for 174 days (until there 
was a gap of >30 days) compared with 122 days for those 
taking typical agents (p < 0.001). Sensitivity analyses using 
period 2 revealed similar results. However, levels of treat-Neuropsychiatric Disease and Treatment 2007:3(2) 280
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ment persistence with atypical agents saw a decline between 
the two study periods, whereas levels of treatment persistence 
with typical agents remained more or less the same. Despite 
this reduced gap between the two classes of drugs between 
period 1 and period 2, the differences in the levels of treat-
ment persistence between typical and atypical antipsychotic 
agents remained signiﬁ  cant (p < 0.001). 
Tables 3 and 4 present treatment persistence in terms of 
mean number of days on the index drug among those with 
one prescription episode, as well as treatment persistence 
for each prescription episode among those with two or 
three prescription episodes, respectively. As revealed in 
Tables 3 and 4, the conventional approach in calculating 
treatment persistence included the prescription episode 
among patients with only one prescription episode, the ﬁ  rst 
prescription episode among those with two prescription 
episodes, and the ﬁ  rst prescription episode among those 
with three prescription episodes (shaded columns). Among 
patients with one prescription episode, initiators of atypical 
antipsychotic agents had signiﬁ  cantly longer mean number 
of treatment days than initiators of typical antipsychotic 
agents (p < 0.001). However, the differences in the level of 
treatment persistence between the two classes of antipsy-
chotic agents were trivial when using the ﬁ  rst prescription 
episodes among patients with two or three prescription 
episodes. On the other hand, of the prescription episodes 
that are not included in the conventional approach in cal-
culating treatment persistence, we found that initiators of 
atypical agents had signiﬁ  cantly better treatment persistence 
than initiators of typical agents (p < 0.001). These ﬁ  ndings, 
which were also observed when we analyzed data from 
period 2 as well as using >30 days in deﬁ  ning treatment 
discontinuation, suggest that the conventional approach 
tends to underestimate the gap in treatment persistence 
between the typical and atypical agents.
These ﬁ  ndings highlight the need to incorporate all 
prescription episodes in the measurement of treatment 
persistence. The incorporation of all prescription episodes 
tended to represent routine clinical practices as a number 
of studies had indicated that switching across antipsychotic 
agents was quite common among patients with schizophre-
nia (Ren et al 2003, 2005a). As shown in Table 5 (see col-
umns subtitled “all episodes”), we included all prescription 
episodes in the calculation of treatment persistence ﬁ  rst by 
taking the sum of the number of days staying on the index 
drug for patients with two or three treatment episodes, and 
then by taking the average number of days staying on the 
index drug across the three patient groups, ie, those with 
one, two, or three treatment episodes. However, what we 
obtained from this approach was a measure that very much 
resembled the Medication Possession Ratio (MPR), a com-
monly used measure of patient adherence with medication 
treatment (Sclar et al 1991, 2001). This particular approach 
has one drawback, that is, by lumping together patients with 
different number of prescription episodes, one would not 
be able to capture the differences in treatment persistence 
between patients with one prescription episode and those 
with multiple prescription episodes. As discussed earlier, 
patients with multiple prescription episodes might represent 
more complicated cases of schizophrenia.
Table 1 Percentage of patients with different number of treatment episodes, by period and deﬁ  nition of treatment discontinuation
 10/1/1999–3/31/2002  10/1/2002–3/31/2005
 Gap  ≥15 daysa Gap  ≥30 daysa   Gap  >15  daysa Gap  >30  daysa
Drug class  N  # of episodes (%)  # of episodes (%)   N  # of episodes (%)     # of episodes (%) 
    1  2  3  4+   1 2 3  4+      1 2  3  4+    1 2 3  4+ 
Atypical  agents  17,390  74.6  18.3  5.5  1.6  83.1 14.0 2.6 0.3  22,629  74.6 18.0  5.6 1.8  79.9 16.2 3.6 0.3
Typical  agents  4,001  74.0  18.9  5.7  1.5  80.6 16.4 2.8 0.3  3,370  72.8 19.4  6.3 1.4  79.9 16.2 3.6 0.3
aTreatment persistence is deﬁ  ned as the # of days on the index drug(s) within one year following initiation until a gap of ≥15 or ≥30 days.
Table 2 Conventional approach to measuring treatment persistence, or mean number of days on the target drug following initiation, 
by period and deﬁ  nition of treatment discontinuation
 10/1/1999–3/31/2002    10/1/2002–3/31/2005
Drug class    Gap ≥15 days  Gap ≥30 days    Gap ≥15 days  Gap ≥30 days
  N  Mean ± SD  Mean ± SD  N  Mean ± SD  Mean±SD
Atypical agents  17,094  150 ± 120  174 ± 128  22,429  135 ± 117  154 ± 125
Typical agents  3,933  107 ± 107  122 ± 115  3,324  110 ± 106  125 ± 116
T-tests of means indicate that all differences between typical and atypical agents are statistically signiﬁ  cant at p < 0.001.Neuropsychiatric Disease and Treatment 2007:3(2) 281
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Table 3  Treatment persistence, by the number of treatment episodes and period (using a gap of ≥15 days as discontinuation of 
medications)
 Period  1  (10/1/1999–3/31/2002)
Drug class  1 episode    2 episodes      3 episodes 
  Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  (3) Mean ± SD  N
Atypical agents  179 ± 142  12,856  65 ± 57  147 ± 130  3,253  55 ± 45  49 ± 35  113 ± 110  985
Typical agents  125 ± 127  2,877  61 ± 54  106 ± 104  797  53 ± 40  44 ± 30  83 ± 82  257
  Period 2 (10/1/2002–3/31/2005)
Drug class  1 episode    2 episodes      3 episodes 
  Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  (3) Mean ± SD  N
Atypical agents  160 ± 139  16,684  64 ± 56  135 ± 125  4,416  53 ± 41  52 ± 37  117 ± 112  1,329
Typical agents  127 ± 124  2,469  63 ± 57  114 ± 112  659  51 ± 42  42 ± 31  104 ± 110  196
The conventional approach in calculating treatment persistence included the prescription episode among patients with only one prescription episode, the ﬁ  rst prescription 
episode among those with two prescription episodes, and the ﬁ  rst prescription episode among those with three prescription episodes (shaded columns).
To distinguish patients with one prescription from those 
with two or three prescriptions or treatment episodes, we 
offered an alternative approach, which was treatment epi-
sode-speciﬁ  c in which treatment persistence with typical and 
atypical antipsychotic agents was measured separately for 
patients with one, two, or three treatment episodes within 
one year following the initiation of the target drug. The 
results presented in Table 5 indicate that consistent with 
the conventional approach, patients who were initiated on 
atypical agents had better treatment persistence than those 
who were initiated on typical agents in all three comparison 
groups, ie, those with one prescription, those with two treat-
ment episodes, and those with three treatment episodes. In 
addition, levels of treatment persistence exhibited variation 
for patients with one, two, or three prescriptions. Generally 
speaking, among patients with one prescription, initiators of 
typical agents tended to fare worst in the level of treatment 
persistence. This ﬁ  nding suggests that conventional approach 
in calculating treatment persistence tends to underestimate 
the gap between typical and atypical agents. Take study 
period 1 and treatment discontinuation using a gap of >15 
days as an example. Using conventional approach, initiators 
of atypical agents stayed on the treatment 43 days longer 
than initiators of typical agents, whereas using our episode-
speciﬁ  c approach among patients with one prescription, 
initiators of atypical agents remained on the treatment 54 
days longer than initiators of typical agents. Similar ﬁ  ndings 
were also observed using data from study period 2 and using 
a gap of >30 days as treatment discontinuation.
Discussions and conclusions
Over the past two decades, interest has increased in studies 
on treatment persistence with antipsychotic agents (Lehman 
and Steinwachs 1998; Valenstein et al 2002; Lehman et al 
2004; Lieberman et al 2005; Ren et al 2006). A number 
of studies have reported that poor treatment persistence 
with antipsychotic agents is a common problem among 
patients with schizophrenia (Docherty et al 2003; Tafesse 
et al 2003), which results in relapse of schizophrenic symp-
toms, increased outpatient visits, hospital admissions, and 
Table 4  Treatment persistence, by the number of treatment episodes and period (using a gap of >30 days as discontinuation of 
medications)
 Period  1  (10/1/1999–3/31/2002)
Drug class  1 episode    2 episodes      3 episodes 
  Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  (3) Mean ± SD  N
Atypical agents  197 ± 143  14,352  68 ± 57  151 ± 97  2,505  50 ± 38  51 ± 35  114 ± 111  480
Typical agents  139 ± 133  3,126  62 ± 53  113 ± 112  707  54 ± 38  42 ± 27  88 ± 88  156
  Period 2 (10/1/2002–3/31/2005)
Drug class  1 episode    2 episodes      3 episodes 
  Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  N  (1) Mean ± SD  (2) Mean ± SD  (3) Mean ± SD  N
Atypical agents  174 ± 141  18,523  67 ± 57  139 ± 126  3,305  51 ± 37  47 ± 32  114 ± 107  712
Typical agents  141 ± 130  2,698  61 ± 61  133 ± 127  546  57 ± 45  46 ± 30  68 ± 64  109
The conventional approach in calculating treatment persistence included the prescription episode among patients with only one prescription episode, the ﬁ  rst prescription 
episode among those with two prescription episodes, and the ﬁ  rst prescription episode among those with three prescription episodes (shaded columns).Neuropsychiatric Disease and Treatment 2007:3(2) 282
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associated unnecessary medical expenses (Grogg et al 2002; 
Lacro et al. 2002; Docherty et al 2003; Tafesse et al 2003). 
Recognizing the importance of treatment persistence to 
the sustained control of the symptoms of schizophrenia, 
prior studies have compared treatment persistence between 
typical and atypical antipsychotic agents, but yielded 
inconsistent ﬁ  ndings. 
In this study, we offered an alternative approach to the 
measurement of treatment persistence. The justiﬁ  cation for 
this alternative approach is based on the observation that 
as many as 25% of the patients included in the study had 
at least two prescriptions of the same agent within one year 
following the initiation of the target drug. A close examina-
tion of the episode-speciﬁ  c mean number of treatment days 
revealed that for patients with multiple prescriptions, levels 
of treatment persistence tended to be universally lower at the 
initial episode(s), but much higher at the last episodes. This 
ﬁ  nding has important implication for the conventional ap-
proach in measuring treatment persistence. On the one hand, 
the conventional approach used only the ﬁ  rst prescription, 
which combined the single prescription for patients who had 
one prescription with the two ﬁ  rst prescriptions for patients 
who had two or three treatment episodes, respectively. On 
the other hand, the conventional approach excluded two 
treatment episodes (the last episodes for patients with two or 
three prescriptions). Thus inclusion and exclusion criteria as-
sociated with the conventional approach are problematic and 
the results based on the approach are likely to be biased.
Recognizing that patients with one prescription might 
be different from those with two or three prescriptions, 
we advocated for an alternative approach in measuring 
treatment persistence, ie, the treatment episode-speciﬁ  c ap-
proach. This approach will enable us to distinguish patients 
with one prescription from those with two or three treat-
ment episodes. As discussed earlier, patients with multiple 
treatment episodes might represent more complicated cases 
of schizophrenia. By comparing episode-speciﬁ  c treat-
ment persistence, the alternative approach provided a fair 
comparison in treatment persistence across antipsychotic 
agents by avoiding the potential bias against those anti-
psychotic agents, which are more likely to be prescribed 
to patients who present with more severe mental diseases 
and therefore more likely to switch back and forth between 
medications.
It is important to note three limitations of the study. 
First, the study included predominantly male patients from 
the VA health care services where female representation is 
typically low. We do not know whether the patterns of treat-
ment persistence across antipsychotic agents observed in the 
present study are unique to male patients. As such, the results 
may not be generalizable to female patients. It is possible 
that male and female patients may have different responses 
to antipsychotic agents in terms of efﬁ  cacy or effectiveness 
as well as tolerability of side-effects, a subject that requires 
further research. Second, the study only included three typi-
cal antipsychotic agents, which may not be representative of 
the ﬁ  rst generation of antipsychotic agents. More research is 
needed to extend to other typical agents, especially those that 
are most commonly prescribed. Similarly, future research 
needs to analyze atypical agents not only at the class level 
but also at the individual drug level. Finally, due to the 
nature of observational study, ie, without implementing 
the randomized assignment rules, the results of the study 
can be affected by selection biases. Despite the fact that 
observational studies represent the spectrum of routine 
medical practice better than randomized experiments, it is 
Table 5  An alternative measure of treatment persistence, by treatment episodes, period, and deﬁ  nition of treatment discontinuation
  Period 1 (10/1/1999–3/31/2002)  Period 2 (10/1/2002–3/31/2005) 
 Gap  ≥15 days as treatment discontinuation  Gap ≥15 days as treatment discontinuation
 All  episodes  Episode-speciﬁ  c  All episodes  Episode-speciﬁ  c 
Drug class      1 episode  2 episodes  3 episodes    1 episode  2 episodes  3 episodes 
  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD
Atypical agents  187 ± 153   179 ± 142  212 ± 187  217 ± 190  171 ± 150  \ ± 139  199 ± 181  222 ± 190
Typical agents  137 ± 135   125 ± 127  167 ± 158  180 ± 152  141 ± 136  127 ± 124  177 ± 169  197 ± 183
 Gap  ≥30 days as treatment discontinuation  Gap ≥30 days as treatment discontinuation
 All  episodes  Episode-speciﬁ  c  All episodes  Episode-speciﬁ  c 
Drug class      1 episode  2 episodes  3 episodes    1 episode  2 episodes  3 episodes 
  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD
Atypical agents  201 ± 146   197 ± 143  219 ± 154  215 ± 184  180 ± 148  174 ± 141  206 ± 183  212 ± 176
Typical agents  147 ± 139   139 ± 133  175 ± 165  184 ± 153  151 ± 140  141 ± 130  194 ± 188  171 ± 139
T-tests of means indicate that all differences between typical and atypical agents are statistically signiﬁ  cant at p < 0.001. Neuropsychiatric Disease and Treatment 2007:3(2) 283
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important for future observational studies to use statisti-
cal techniques, such as propensity scores and sensitivity 
analyses, to minimize the confounding errors associated 
with observational studies.
Despite these limitations, the results of the study have 
important implications for the care of patients with schizo-
phrenia. With several antipsychotic drugs available, physi-
cians are increasingly confronted with many critical choices 
in selecting medications that tend to beneﬁ  t the patients. Since 
poor treatment persistence contributed to an estimated 40% 
relapses (Weiden and Zygmund 1997), levels of treatment 
persistence have become an increasingly important factor in 
prescription choices by physicians of different antipsychotic 
agents. However, considering the inappropriateness of the 
conventional approach in measuring treatment persistence 
as well as the limitations of the present study, more research 
is needed to examine the extent to which adjunctive use of 
other agents, a common practice among patients with schizo-
phrenia (Ren et al 2004), will inﬂ  uence levels of treatment 
persistence. Future research should also assess the impact 
of poor treatment persistence on a wide spectrum of patient 
outcomes (Ren et al 2005b). A more comprehensive assess-
ment using appropriate analytic methods should provide phy-
sicians with a better knowledge about treatment persistence 
associated with different antipsychotic agents and help them 
make prescription choices that will ultimately improve the 
care of schizophrenia.
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